Effect of dapagliflozin in patients with heart failure

Area of Science:

• Cardiology
• Pharmacology
• Endocrinology

Background:

• Heart failure with reduced ejection fraction (HFrEF) is a major cause of cardiovascular morbidity and mortality.
• Current treatments for HFrEF have limitations in further reducing adverse outcomes.
• Sodium-glucose cotransporter-2 (SGLT2) inhibitors, primarily used for type 2 diabetes, have shown cardioprotective effects.

Purpose of the Study:

• To evaluate the efficacy and safety of dapagliflozin in patients with HFrEF, irrespective of diabetes status.
• To assess the impact of dapagliflozin on cardiovascular outcomes, including cardiovascular death and heart failure hospitalizations.
• To determine the role of SGLT2 inhibition in managing HFrEF.

Main Methods:

• A large-scale, randomized, double-blind, placebo-controlled trial (DAPA-HF) was conducted.
• Participants with symptomatic HFrEF and LVEF ≤ 40% were randomized to dapagliflozin or placebo.
• The primary composite endpoint was cardiovascular death or worsening heart failure.

Main Results:

• Dapagliflozin significantly reduced the risk of the primary composite endpoint by 26% compared to placebo (hazard ratio 0.74; 95% CI 0.65–0.85; P < 0.001).
• There was a significant reduction in heart failure hospitalizations and cardiovascular death in the dapagliflozin group.
• Adverse events, including genital infections and volume depletion, were generally well-tolerated.

Conclusions:

• Dapagliflozin is effective in reducing cardiovascular death and heart failure hospitalizations in patients with HFrEF.
• SGLT2 inhibition represents a novel and important therapeutic strategy for managing HFrEF.
• Dapagliflozin should be considered as a standard treatment for patients with HFrEF.